Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1738]

Current and future immune approaches in precision medicine

Prof Jean -Yves Blay - Centre Léon Bérard, Lyon, France

Current and future immune approaches in precision medicine ( Prof Jean -Yves Blay - Centre Léon Bérard, Lyon, France )

Synthetic lethality as a basis to select drug combinations

Prof René Bernards - Netherlands Cancer Institute, Amsterdam, Holland

Synthetic lethality as a basis to select drug combinations ( Prof René Bernards - Netherlands Cancer Institute, Amsterdam, Holland )

Novel models to personalise cancer therapeutics

Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden

Novel models to personalise cancer therapeutics ( Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden )

Low dose exemestane usage in breast cancer

Dr Davide Serrano - European Institute of Oncology, Milan, Italy

Low dose exemestane usage in breast cancer ( Dr Davide Serrano - European Institute of Oncology, Milan, Italy )

BRCA1 and BRCA2 genes and hereditary breast cancers

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

BRCA1 and BRCA2 genes and hereditary breast cancers ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany

Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

Phase Ib/II study of nivolumab in combination with azacytidine in patients with...

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

Dr Yi Lin - Mayo Clinic, Rochester, USA

ZUMA1 trial of CD19 CAR T cells for aggressive NHL ( Dr Yi Lin - Mayo Clinic, Rochester, USA )

Diverse T lymphocyte population fights leukaemia more effectively

Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany

Diverse T lymphocyte population fights leukaemia more effectively ( Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany )

Delayed exposure to common infections causes acute childhood leukaemia

Dr Julia Hauer - Clinic for Pediatric Oncology, Haematology and Clinical...

Delayed exposure to common infections causes acute childhood leukaemia ( Dr Julia Hauer - Clinic for Pediatric Oncology, Haematology and Clinical Immunology, Düsseldorf, Germany )

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed...

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

$Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )$

More from ecancer